Diabetes, Obesity and Metabolism

Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes
pp. 121-129(9)
Authors: Williams K.V.; Kelley D.E.

Metformin and lactic acidosis in diabetic humans
pp. 131-137(7)
Authors: Lalau J-D.; Race J-M.

Using dose–response characteristics of therapeutic agents for treatment decisions in type 2 diabetes
pp. 139-147(9)
Author: Garber A.J.

Cosegregation of obesity with familial aggregation of type 2 diabetes mellitus
pp. 149-154(6)
Authors: Ramachandran A.; Snehalatha C.; Satyavani K.; Sivasankari S.; Vijay V.

Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione*
pp. 155-163(9)
Authors: Yakubu-Madus F.E.; Stephens T.W.; Johnson W.T.

Diabetes-induced biochemical changes in rat lens: attenuation of cataractogenesis by pyruvate
pp. 165-174(10)
Authors: Zhao W.; Devamanoharan P.S.; Henein M.; Ali A.H.; Varma S.D.

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
pp. 175-187(13)
Authors: Fujioka K.; Seaton T.B.; Rowe E.; Jelinek C.A.; Raskin P.; Lebovitz H.E.; Weinstein S.P.; Group T.S.C.S.

Troglitazone reduces plasma levels of tumour necrosis factor- in obese patients with type 2 diabetes
pp. 189-191(3)
Authors: Katsuki A.; Sumida Y.; Murata K.; Furuta M.; Araki-Sasaki R.; Tsuchihashi K.; Hori Y.; Yano Y.; Gabazza E.C.; Adachi Y.

News and Views
pp. 193-201(9)